Non-Invasive Genomic Monitoring to Improve Transplant Outcomes

TruGraf Science

Healthcare Professionals

Patients & Caregivers

Transplant Genomics aims to improve transplant outcomes through molecular diagnostic tests that detect early signs of graft injury, differentiate among actionable causes, and enable optimization of therapy.

~35% of patients receive a surveillance biopsy in the first year

≥75% of patients who have surveillance biopsies show normal histology and the vast majority could have been spared an invasive procedure if tested with TruGraf®

≥20% of patients show subclinical acute rejection

Attend our Next Webinar August 12th, 2021

TruGraf® aids physicians with non-invasive monitoring to rule out silent rejection.